Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

534 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Is weight gain preventable in women with early breast cancer undergoing chemotherapy? A real-world study on dietary pattern, physical activity, and body weight before and after chemotherapy.
Pedersini R, Laganà M, Bosio S, Zanini B, Cosentini D, di Mauro P, Alberti A, Schivardi G, Laini L, Ippolito G, Amoroso V, Vassalli L, Simoncini EL, Berruti A, Donato F. Pedersini R, et al. Among authors: berruti a. Breast Cancer Res Treat. 2023 Dec;202(3):461-471. doi: 10.1007/s10549-023-07095-8. Epub 2023 Sep 11. Breast Cancer Res Treat. 2023. PMID: 37695400 Free PMC article.
Magnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapy.
Bodini M, Berruti A, Bottini A, Allevi G, Fiorentino C, Brizzi MP, Bersiga A, Generali D, Volpi D, Marini U, Aguggini S, Tampellini M, Alquati P, Olivetti L, Dogliotti L. Bodini M, et al. Among authors: berruti a. Breast Cancer Res Treat. 2004 Jun;85(3):211-8. doi: 10.1023/B:BREA.0000025409.69516.23. Breast Cancer Res Treat. 2004. PMID: 15111758
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study.
Berruti A, Fazio N, Ferrero A, Brizzi MP, Volante M, Nobili E, Tozzi L, Bodei L, Torta M, D'Avolio A, Priola AM, Birocco N, Amoroso V, Biasco G, Papotti M, Dogliotti L. Berruti A, et al. BMC Cancer. 2014 Mar 14;14:184. doi: 10.1186/1471-2407-14-184. BMC Cancer. 2014. PMID: 24628963 Free PMC article. Clinical Trial.
Leptomeningeal metastasis from solid tumors: a diagnostic and therapeutic challenge.
Passarin MG, Sava T, Furlanetto J, Molino A, Nortilli R, Musso AM, Zaninelli M, Franceschi T, Orrico D, Marangoni S, Dealis C, Graiff C, Filippo R, Grisanti S, Simoncini E, Vassalli L, Berruti A, Pedersini R. Passarin MG, et al. Among authors: berruti a. Neurol Sci. 2015 Jan;36(1):117-23. doi: 10.1007/s10072-014-1881-7. Epub 2014 Jul 16. Neurol Sci. 2015. PMID: 25022241
Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies.
Berruti A, Amoroso V, Gallo F, Bertaglia V, Simoncini E, Pedersini R, Ferrari L, Bottini A, Bruzzi P, Sormani MP. Berruti A, et al. J Clin Oncol. 2014 Dec 1;32(34):3883-91. doi: 10.1200/JCO.2014.55.2836. Epub 2014 Oct 27. J Clin Oncol. 2014. PMID: 25349292 Review.
Neoadjuvant Treatment Approach: The Rosetta Stone for Breast Cancer?
Generali D, Ardine M, Strina C, Milani M, Cappelletti MR, Zanotti L, Forti M, Bedussi F, Martinotti M, Amoroso V, Sigala S, Simoncini E, Berruti A, Bottini A. Generali D, et al. Among authors: berruti a. J Natl Cancer Inst Monogr. 2015 May;2015(51):32-5. doi: 10.1093/jncimonographs/lgv019. J Natl Cancer Inst Monogr. 2015. PMID: 26063883
534 results